Key clinical point: Rates of locoregional recurrence after surgery were different for different molecular subtypes of breast cancer (BC).
Major finding: Compared with patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (ERBB2− aka HER2−) BC, those with HR−/ERBB2+ BC had approximately three times worse ipsilateral breast tumor recurrence (IBTR)-free survival (adjusted hazard ratio [aHR] 2.95; 95% CI 2.15-4.06), whereas patients with triple-negative BC had the worst regional recurrence-free survival (aHR 2.95; 95% CI 2.37-3.67) and contralateral BC-free survival (aHR 2.12; 95% CI 1.64-2.75). IBTR was lower in older patients with BC (P < .001).
Study details: Findings are from a retrospective cohort study including 16,462 women with BC who underwent surgery.
Disclosures: This study was funded by the Ministry of Health and Welfare, Republic of Korea. Some authors declared being members of a board of directors, stockholders of, or receiving grants from various sources.
Source: Cheun JH et al. Locoregional recurrence patterns in patients with different molecular subtypes of breast cancer. JAMA Surg. 2023 (Jun 21). Doi: 10.1001/jamasurg.2023.2150